Sarcoidosis led to thrombotic microangiopathy (TMA), a rare blood disorder, and associated severe kidney damage and blood-related abnormalities in…
Teresa Carvalho, MS
Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Teresa Carvalho, MS
People with sarcoidosis who live in neighborhoods lacking economic and social resources have lower lung function and faster lung…
Xentria has raised $25 million in funding to further the development of XTMAB-16, its experimental antibody therapy for…
About 35 out of every 100,000 people with private insurance in the U.S. are estimated to have sarcoidosis, and…
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases.
Protalix Biotherapeutics and SarcoMed USA have entered into an exclusive worldwide license agreement to advance PRX-110 (alidornase…
Corticosteroids, a type of anti-inflammatory medication, is the most-prescribed treatment for people with sarcoidosis, a study in a…